- Home
- XNCR
XNCR
Xencor Inc.
as 12-20-2024 3:44pm EST
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 1.7B | IPO Year: | 2013 |
| Target Price: | $36.33 | AVG Volume (30 days): | 850.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.31 - $27.24 | Next Earning Date: | 11-06-2024 |
| Revenue: | $85,164,000 | Revenue Growth: | -41.37% |
| Revenue Growth (this year): | -64.96% | Revenue Growth (next year): | 89.22% |
Stock Insider Trading Activity of Xencor Inc. (XNCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Montgomery Alan Bruce | XNCR | Director | Dec 2 '24 | Sell | $27.03 | 14,722 | $397,930.92 | 9,140 | |
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Nov 21 '24 | Sell | $24.07 | 49,278 | $1,186,362.92 | 352,615 | |
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Nov 13 '24 | Sell | $24.02 | 3,366 | $80,841.90 | 352,615 | |
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Nov 11 '24 | Sell | $23.48 | 68,684 | $1,612,638.50 | 200,104 | |
| GUSTAFSON KURT A | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 9,490 | |
| GORMAN KEVIN CHARLES | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,654 | $54,884.72 | 8,392 | |
| Feigal Ellen | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 8,490 | |
| Montgomery Alan Bruce | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 1,853 | $38,320.04 | 9,140 | |
| ROSA-BJORKESON DAGMAR | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 8,490 | |
| RANIERI RICHARD J | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 8,490 |
Latest Xencor Inc. News
XNCR Breaking Stock News: Dive into XNCR Ticker-Specific Updates for Smart Investing
Argus Research
5 days ago
XNCR: Rating increased to a HOLD
Zacks
10 days ago
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
MT Newswires
10 days ago
Wells Fargo Initiates Xencor at Overweight With $37 Price Target
Argus Research
12 days ago
XNCR: Lowering target price to $23.00
Zacks
18 days ago
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
Argus Research
19 days ago
XNCR: Raising target price to $24.00
MT Newswires
20 days ago
Piper Sandler Upgrades Xencor to Overweight, Price Target is $30
Argus Research
a month ago
XNCR: Raising target price to $23.00
Compare XNCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XNCR Xencor Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.